BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 28801862)

  • 1. Feasibility, comparability, and reliability of the standard gamble compared with the rating scale and time trade-off techniques in Korean population.
    Kim SH; Lee SI; Jo MW
    Qual Life Res; 2017 Dec; 26(12):3387-3397. PubMed ID: 28801862
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Feasibility, validity and test-retest reliability of scaling methods for health states: the visual analogue scale and the time trade-off.
    Badia X; Monserrat S; Roset M; Herdman M
    Qual Life Res; 1999 Jun; 8(4):303-10. PubMed ID: 10472162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validity, feasibility and acceptability of time trade-off and standard gamble assessments in health valuation studies: a study in a multiethnic Asian population in Singapore.
    Wee HL; Li SC; Xie F; Zhang XH; Luo N; Feeny D; Cheung YB; Machin D; Fong KY; Thumboo J
    Value Health; 2008 Mar; 11 Suppl 1():S3-10. PubMed ID: 18387064
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validity of EuroQOL-5D, time trade-off, and standard gamble for age-related macular degeneration in the Singapore population.
    Au Eong KG; Chan EW; Luo N; Wong SH; Tan NW; Lim TH; Wagle AM
    Eye (Lond); 2012 Mar; 26(3):379-88. PubMed ID: 22222257
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Health State Utility Measures in Patients With Head and Neck Cancer.
    Noel CW; Lee DJ; Kong Q; Xu W; Simpson C; Brown D; Gilbert RW; Gullane PJ; Irish JC; Huang SH; O'Sullivan B; Goldstein DP; de Almeida JR
    JAMA Otolaryngol Head Neck Surg; 2015 Aug; 141(8):696-703. PubMed ID: 26204439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The comparability and reliability of five health-state valuation methods.
    Krabbe PF; Essink-Bot ML; Bonsel GJ
    Soc Sci Med; 1997 Dec; 45(11):1641-52. PubMed ID: 9428084
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Test-Retest Reliability of EQ-5D-5L Valuation Techniques: The Composite Time Trade-Off and Discrete Choice Experiments.
    Purba FD; Hunfeld JAM; Timman R; Iskandarsyah A; Fitriana TS; Sadarjoen SS; Passchier J; Busschbach JJV
    Value Health; 2018 Oct; 21(10):1243-1249. PubMed ID: 30314626
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Similar responses to EQ-5D-3L by two elicitation methods: visual analogue scale and time trade-off.
    Wang X; Zhuo L; Ma Y; Cai T; Must A; Xu L; Zhuo L
    BMC Med Res Methodol; 2020 May; 20(1):118. PubMed ID: 32410582
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rating scale, standard gamble, and time trade-off for people with traumatic spinal cord injuries.
    Lin MR; Hwang HF; Chung KP; Huang C; Chen CY
    Phys Ther; 2006 Mar; 86(3):337-44. PubMed ID: 16506870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Valuing Child Health Utility 9D health states with a young adolescent sample: a feasibility study to compare best-worst scaling discrete-choice experiment, standard gamble and time trade-off methods.
    Ratcliffe J; Couzner L; Flynn T; Sawyer M; Stevens K; Brazier J; Burgess L
    Appl Health Econ Health Policy; 2011; 9(1):15-27. PubMed ID: 21033766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What utility scores do mental health service users, healthcare professionals and members of the general public attribute to different health states? A co-produced mixed methods online survey.
    Flood C; Barlow S; Simpson A; Burls A; Price A; Cartwright M; Brini S;
    PLoS One; 2018; 13(10):e0205223. PubMed ID: 30352071
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Experience-Based Swedish TTO and VAS Value Sets for EQ-5D-5L Health States.
    Burström K; Teni FS; Gerdtham UG; Leidl R; Helgesson G; Rolfson O; Henriksson M
    Pharmacoeconomics; 2020 Aug; 38(8):839-856. PubMed ID: 32307663
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Can health utility measures be used in lupus research? A comparative validation and reliability study of 4 utility indices.
    Moore AD; Clarke AE; Danoff DS; Joseph L; Bélisle P; Neville C; Fortin PR
    J Rheumatol; 1999 Jun; 26(6):1285-90. PubMed ID: 10381044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [General population time trade-off values for 42 EQ-5D health states in South Korea].
    Jo MW; Lee SI
    J Prev Med Public Health; 2007 Mar; 40(2):169-76. PubMed ID: 17426430
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chained time trade-off and standard gamble methods. Applications in oesophageal cancer.
    McNamee P; Glendinning S; Shenfine J; Steen N; Griffin SM; Bond J
    Eur J Health Econ; 2004 Feb; 5(1):81-6. PubMed ID: 15452769
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of different valuation methods for population health status measured by the EQ-5D in three European countries.
    Bernert S; Fernández A; Haro JM; König HH; Alonso J; Vilagut G; Sevilla-Dedieu C; de Graaf R; Matschinger H; Heider D; Angermeyer MC;
    Value Health; 2009; 12(5):750-8. PubMed ID: 19490564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Health-related quality of life in patients with uveitis.
    Shamdas M; Bassilious K; Murray PI
    Br J Ophthalmol; 2019 Sep; 103(9):1284-1288. PubMed ID: 30361275
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of caregiver and parenting status on time trade-off and standard gamble utility scores for health state descriptions.
    Matza LS; Boye KS; Feeny DH; Johnston JA; Bowman L; Jordan JB
    Health Qual Life Outcomes; 2014 Apr; 12():48. PubMed ID: 24716709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reporting and valuing one's own health: a think aloud study using EQ-5D-5L, EQ VAS and a time trade-off question among patients with a chronic condition.
    Ernstsson O; Burström K; Heintz E; Mølsted Alvesson H
    Health Qual Life Outcomes; 2020 Dec; 18(1):388. PubMed ID: 33334348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Valuing health-related quality of life. A review of health state valuation techniques.
    Green C; Brazier J; Deverill M
    Pharmacoeconomics; 2000 Feb; 17(2):151-65. PubMed ID: 10947338
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.